895 results on '"Batista, Alzir A."'
Search Results
202. Remarkable Electronic Effect on the meso-Tetra(thienyl)porphyrins
203. Esterification of the free carboxylic group from the lutidinic acid ligand as a tool to improve the cytotoxicity of Ru(ii) complexes
204. In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes
205. Magnetic-field-tuned phase transition of a molecular material from the isolated-spin to the coupled-spin regime
206. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding
207. Palladium(ii) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors
208. Antiparasitic activity and ultrastructural alterations provoked by organoruthenium complexes against Leishmania amazonensis
209. Anti-Proliferative and Anti-Migration Activity of Arene–Ruthenium(II) Complexes with Azole Therapeutic Agents
210. A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis
211. Carbonyl–heterobimetallic Ru(II)/Fe(II)–complexes containing polypyridyl ligands: Synthesis, characterization, cellular viability assays and interactions with biomolecules
212. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors
213. Study of the cytotoxic and genotoxic potential of the carbonyl ruthenium(II) compound,ct‐[RuCl(CO)(dppb)(bipy)]PF6[dppb = 1,4‐bis(diphenylphosphino)butane and bipy = 2,2′‐bipyridine], by in vitro and in vivo assays
214. Syntheses, characterization and X-ray structures of the fac-[RuCl 3(NO)(dppe)] and the trans-[RuCl(NO)(dppe) 2] 2+ species
215. Synthesis of (RuCl(sub.2)(dppb)(PPH(sub.3))) and identification of the cis- and trans-(RuCl(sub.2)(dppb)(phen)) geometrical isomers via (super.31)P((super.1)H) NMR spectroscopy: an undergraduate experiment for inorganic chemistry
216. Polypyridyl ruthenium complexes : novel DNA-intercalating agents against human breast tumor
217. Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis
218. Three-dimensional cell culture models for metallodrug testing: induction of apoptosis and phenotypic reversion of breast cancer cells by the trans-[Ru(PPh3)2(N,N-dimethyl-N-thiophenylthioureato-k2O,S)(bipy)]PF6 complex
219. Heterobimetallic Ru(II)/Fe(II) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
220. Anti-Mycobacterium tuberculosis activity of platinum(II)/N,N-disubstituted-N′-acyl thiourea complexes
221. The trans -[Ru(PPh 3 ) 2 ( N , N -dimethyl- N ′-thiophenylthioureato-k 2 O,S)(bipy)]PF 6 complex has pro-apoptotic effects on triple negative breast cancer cells and presents low toxicity in vivo
222. Abstract A16: Evaluation of the genotoxicity of ruthenium complex, trans-[Ru(ThySMet)(PPh3)2(bipy)]PF6, by comet assay in vitro on breast cells and in vivo
223. Abstract A71: Evaluation of ruthenium complex [Ru(AmSal)(dppe)2]PF6 on the proliferation, morphology, and migration of triple-negative MDA-MB-231 breast tumor cells
224. Ru(II)-Thymine Complex Causes Cell Growth Inhibition and Induction of Caspase-Mediated Apoptosis in Human Promyelocytic Leukemia HL-60 Cells
225. A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells
226. Facile Synthesis and Characterization of Symmetric N-[(Phenylcarbonyl) carbamothioyl]benzamide Thiourea: Experimental and Theoretical Investigations
227. Metal–azole fungistatic drug complexes as anti-Sporothrix spp. agents
228. Ru(ii)–thyminate complexes: new metallodrug candidates against tumor cells
229. cis -[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells
230. Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells
231. Copper(II) complexes with (2-hydroxybenzyl-2-pyridylmethyl)amine–Hbpa: syntheses, characterization and crystal structures of the ligand and [Cu(II)(Hbpa) 2](ClO 4) 2·2H 2O
232. Anti-Mycobacterium tuberculosis and Cytotoxicity Activities of Ruthenium(II)/ Bipyridine/Diphosphine/Pyrimidine-2-thiolate Complexes: The Role of the Non- Coordinated N-Atom
233. On an electrode modified by a supramolecular ruthenium mixed valence ([Ru.sup.II]/[Ru.sup.III]) diphosphine-porphyrin assembly
234. Synthesis of the [(η6-p-cymene)Ru(dppb)Cl]PF6 complex and catalytic activity in the transfer hydrogenation of ketones
235. Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression
236. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells
237. Palladium(II)/ N , N -disubstituted- N ′-acylthioureas complexes as anti- Mycobacterium tuberculosis and anti- Trypanosoma cruzi agents
238. Antitumor and anti-Mycobacterium tuberculosis agents based on cationic ruthenium complexes with amino acids
239. Copper(I)–Phosphine Polypyridyl Complexes: Synthesis, Characterization, DNA/HSA Binding Study, and Antiproliferative Activity
240. A biphosphinic ruthenium complex with potent anti-bacterial and anti-cancer activity
241. Platinum(ii)–chloroquine complexes are antimalarial agents against blood and liver stages by impairing mitochondrial function
242. Polypyridyl Ruthenium Complexes: Novel DNA-Intercalating Agents against Human Breast Tumor
243. Structure/Activity of PtII/N,N-Disubstituted-N’-acylthiourea Complexes: Anti-Tumor and Anti-Mycobacterium tuberculosis Activities
244. Synthesis, Characterization, Cytotoxic Activity, and Interactions with CT-DNA and BSA of Cationic Ruthenium(II) Complexes Containing Dppm and Quinoline Carboxylates
245. Half sandwich Ru(ii)-acylthiourea complexes: DNA/HSA-binding, anti-migration and cell death in a human breast tumor cell line
246. Ruthenium(II) Complexes Containing Anti-Inflammatory Drugs as Ligands: Synthesis, Characterization and in vitro Cytotoxicity Activities on Cancer Cell Lines
247. A Mixed Ligand Platinum(II) Complex: Spectral Analysis, Crystal Structure, Steric Demand of the Ligand, and Bioactivity of cis‐[Pt(PPh3)2(L1‐O,S)]PF6 (L1‐O,S = N,N‐Morpholine‐N′‐benzoylthiourea)
248. Study of the cytotoxic and genotoxic potential of the carbonyl ruthenium(II) compound, ct‐[RuCl(CO)(dppb)(bipy)]PF6 [dppb = 1,4‐bis(diphenylphosphino)butane and bipy = 2,2′‐bipyridine], by in vitro and in vivo assays.
249. Transport of the Ruthenium Complex [Ru(GA)(dppe)2]PF6 into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors.
250. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.